Today: 14 May 2026
Browse Category

Pharmaceuticals 3 January 2026 - 6 January 2026

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly shares fell 3.6% to $1,041.51 in after-hours trading Monday after Novo Nordisk launched a pill version of its Wegovy weight-loss drug in the U.S. Novo’s shares rose 5.2% as investors reacted to new pricing and distribution details. Lilly’s stock traded as low as $1,034 earlier in the session. Investors await commentary at the J.P. Morgan Healthcare Conference and Lilly’s earnings call.
6 January 2026
···
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears

Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears

Xenon Pharmaceuticals shares fell 6.5% to $41.60 Monday afternoon, underperforming biotech peers ahead of next week’s J.P. Morgan Healthcare Conference. The stock traded between $45.21 and $41.45 on volume of 787,000 shares. Cantor Fitzgerald raised its price target to $55 despite the drop. Investors await updates on late-stage epilepsy trial timelines and commercialization plans.
5 January 2026
··
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares fell 6.9% to $63.11 Monday after Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock dropped despite the clearance, tracking weakness across biotech stocks. Investors now await Arrowhead’s obesity data webinar on Jan. 6 and its J.P. Morgan conference presentation Jan. 12.
5 January 2026
···
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly shares dropped 3.4% to $1,043.14 after Novo Nordisk launched U.S. sales of an oral Wegovy weight-loss pill starting at $149 a month. Novo’s move intensified focus on pricing in the obesity drug market. The Health Care Select Sector SPDR ETF fell 1.3%, while Novo Nordisk shares rose 2.9%. Investors are awaiting Lilly’s next earnings update on February 4.
5 January 2026
···
Brand Engagement Network (BNAI) stock rises again premarket as AI pharma deal keeps traders hooked

Brand Engagement Network (BNAI) stock rises again premarket as AI pharma deal keeps traders hooked

Brand Engagement Network shares rose 5.3% to $3.97 in premarket trading Monday, extending Friday’s 62.5% surge. The rally follows disclosure of a $250,000 AI services deal for a top pharmaceutical client. Investors are watching for sustained volume and updates on project timing. The company reported $60,120 in quarterly revenue and $102,715 in cash as of Sept. 30.
5 January 2026
···
Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals shares rose about 1% premarket Monday after Citizens upgraded the stock, citing eased pricing pressure on Linzess. The company last week cut Linzess’s list price by about 50% and forecast 2026 revenue of $450–$475 million. Shares closed up 26.7% Friday at $4.27, with trading volume surging to 85 million. Ironwood remains in a strategic alternatives review and plans a Phase 3 apraglutide trial in 2026.
5 January 2026
··
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Ironwood Pharmaceuticals shares jumped 26.7% Friday to $4.27 after the company issued 2026 guidance, forecasting total revenue of $450 million to $475 million and adjusted EBITDA above $300 million. The company expects 2026 Linzess U.S. net sales of $1.125 billion to $1.175 billion after lowering the drug’s list price on Jan. 1. Investors await a fourth-quarter update on the apraglutide Phase 3 trial and strategic review.
4 January 2026
·
Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics shares fell 6.5% to $72.76 on Friday, marking a seventh straight daily loss and leaving the stock down 29% from its early December peak. About 854,000 shares traded as investors shifted focus to 2026 trial milestones and funding. CEO Nello Mainolfi sold 30,000 shares in a pre-arranged plan on Dec. 31. The company raised $602 million in a December stock offering at $86 per share.
4 January 2026
·
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer shares closed up 1.1% at $25.18 on Friday, after leading U.S. drugmakers in January list-price hikes, including a 15% increase for its COVID vaccine Comirnaty. The stock remains below its 52-week high of $27.69. Investors await Pfizer’s Feb. 3 earnings update and monitor upcoming U.S. jobs and inflation data.
3 January 2026
····
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck shares rose 1.2% to $106.45 Friday after Nasdaq set Jan. 6 as the expiration for its $9.2 billion cash tender offer for Cidara Therapeutics. Cidara shares will be halted after Jan. 6 and suspended Jan. 8 if the merger closes as planned. Merck’s move snapped a three-day losing streak, leaving the stock just below its 52-week high. About 10 million shares traded, below the 50-day average.
3 January 2026
···
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

U.S. drugmakers are raising list prices on at least 350 branded medicines for 2026, with a median increase of about 4%, Reuters reported. The Health Care Select Sector SPDR Fund (XLV) closed up 0.46% at $155.51 Friday. Pfizer, Eli Lilly, and Johnson & Johnson all posted gains. Traders are watching next week’s U.S. jobs data and upcoming healthcare earnings.
3 January 2026
····
Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly shares closed up 0.53% at $1,080.36 Friday, then slipped 0.17% after hours. Drug pricing remains in focus as list-price resets and Medicare negotiations begin the year. Zacks upgraded Lilly to “strong-buy” and Reuters reported a 40% list-price cut for Jardiance. CEO David Ricks will speak at the J.P. Morgan Healthcare Conference on January 13.
3 January 2026
··
1 … 19 20 21 22 23 … 40

Stock Market Today

  • Kevin Warsh Set to Reshape Fed Policy, Risks Market Stability
    May 14, 2026, 4:23 AM EDT. Kevin Warsh begins his term as Federal Reserve chair on May 15, aiming to delever the Fed's $6.7 trillion balance sheet by selling trillions in long-term Treasury bonds. This move could push bond yields higher, effectively raising borrowing costs despite no planned interest rate hikes, potentially unsettling the historically expensive U.S. stock market. Warsh also proposes redefining inflation, moving away from the rigid 2% target to a vaguer concept of price stability, a shift that may introduce uncertainty into monetary policy. These changes pose risks to Wall Street's current bull market momentum, which benefits from low interest rates fueling growth sectors like artificial intelligence.

Latest articles

Marvell Technology Stock Jumps as Wall Street Chases the AI Networking Trade Before Earnings

Marvell Technology Stock Jumps as Wall Street Chases the AI Networking Trade Before Earnings

14 May 2026
Marvell Technology shares jumped 8.18% to close at $177.95 Wednesday, hitting a 52-week high before trading at $182.50 after hours. BofA and B. Riley raised price targets above $200 this week, citing AI data-center demand. Marvell will report first-quarter fiscal 2027 results on May 27. The company posted $8.195 billion in fiscal 2026 revenue, up 42% year over year.
Ford Stock Just Had Its Best Day in Six Years. The Surprise Driver Was Energy Storage

Ford Stock Just Had Its Best Day in Six Years. The Surprise Driver Was Energy Storage

14 May 2026
Ford shares surged 13% Wednesday, their biggest one-day gain in six years, after Morgan Stanley highlighted the company’s new energy-storage business. The stock closed at $13.57. Ford plans to invest $2 billion in the unit, aiming to deliver its first systems in 2027 and deploy at least 20 gigawatt-hours annually. The company reported Q1 revenue of $43.3 billion and raised its full-year profit outlook.
Nvidia’s China H200 Chip Door Just Opened. The Money Still Isn’t Moving

Nvidia’s China H200 Chip Door Just Opened. The Money Still Isn’t Moving

14 May 2026
The U.S. has approved Nvidia to sell H200 AI chips to about 10 Chinese firms, including Alibaba and Tencent, but no shipments have occurred as Chinese buyers hold back under Beijing’s guidance. Nvidia CEO Jensen Huang is in Beijing with President Trump’s delegation ahead of the company’s May 20 earnings report. Lenovo confirmed it is cleared to distribute the chips in China.
Nokia Stock Surges Again as Cisco’s AI Orders Put New Heat Under the Network Trade

Nokia Stock Surges Again as Cisco’s AI Orders Put New Heat Under the Network Trade

14 May 2026
Nokia shares jumped about 10% in Helsinki Thursday, extending gains after Cisco reported $5.3 billion in AI infrastructure orders and raised its full-year outlook. Nokia launched new agentic AI tools for broadband networks and named Siemens executive Emma Falck as president of Mobile Infrastructure. The stock approached levels last seen 16 years ago.
Go toTop